UY23844A1 - ANTIVIROSIC AGENTS. - Google Patents
ANTIVIROSIC AGENTS.Info
- Publication number
- UY23844A1 UY23844A1 UY23844A UY23844A UY23844A1 UY 23844 A1 UY23844 A1 UY 23844A1 UY 23844 A UY23844 A UY 23844A UY 23844 A UY23844 A UY 23844A UY 23844 A1 UY23844 A1 UY 23844A1
- Authority
- UY
- Uruguay
- Prior art keywords
- derivative
- riboflavin
- flavin
- rivoflavin
- vitamin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invencion se refiere a agentes antivirosicos, en particular para el tratamiento de seres humanos y animales, para aliviar y curar los efectos perniciosos causados por las enfermedades virosicas, especialmente el HIV. La rivoflavina es un compuesto conocido, que también se conoce E101; lactoflavina; Riboflavina; Vitamina B2, Vitamina G, etc. Por consiguiente, la presente invención en un aspecto proporciona el uso de una flavina, especialmente rivoflavina o un derivado de la misma, para la preparación de un medicamento para el tratamiento de enfermedades virósicas. El uso de acuerdo con la invención , la riboflavina u otras flavinas pueden ser usadas como tales o como un derivado de flavina puede ser cualquir derivaso y el derivado de flavina puede ser cuualquier derivado que es seguro paa el uso en seres humanos o animales. Preferentemente, sin embargo, en el caso de la riboflavina el derivado es una sal de riboflavina y preferentemente la sal de riboflavina es fosfato sódico de riboflavina o tetrabutirato de riboflavina. La flavina o el derivado deberían tener alta pureza y evitarse la contaminación con ingredientes extrañosThe present invention relates to antiviral agents, in particular for the treatment of humans and animals, to alleviate and cure the harmful effects caused by viral diseases, especially HIV. Rivoflavin is a known compound, which is also known E101; lactoflavin; Riboflavin; Vitamin B2, Vitamin G, etc. Accordingly, the present invention in one aspect provides the use of a flavin, especially rivoflavin or a derivative thereof, for the preparation of a medicament for the treatment of viral diseases. The use according to the invention, riboflavin or other flavins can be used as such or as a flavin derivative can be any derivative and the flavin derivative can be any derivative that is safe for use in humans or animals. Preferably, however, in the case of riboflavin the derivative is a riboflavin salt and preferably the riboflavin salt is riboflavin sodium phosphate or riboflavin tetrabutyrate. Flavin or derivative should be of high purity and contamination with foreign ingredients should be avoided
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939321558A GB9321558D0 (en) | 1993-10-19 | 1993-10-19 | Anti-viral agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY23844A1 true UY23844A1 (en) | 1995-03-28 |
Family
ID=10743784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY23844A UY23844A1 (en) | 1993-10-19 | 1994-10-19 | ANTIVIROSIC AGENTS. |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0739208A1 (en) |
| JP (1) | JPH09505804A (en) |
| CN (1) | CN1140992A (en) |
| AP (1) | AP620A (en) |
| AU (1) | AU7943794A (en) |
| BG (1) | BG100599A (en) |
| BR (1) | BR9407862A (en) |
| CA (2) | CA2123825A1 (en) |
| CO (1) | CO4520283A1 (en) |
| CZ (1) | CZ113796A3 (en) |
| EE (1) | EE9600057A (en) |
| GB (2) | GB9321558D0 (en) |
| HR (1) | HRP940688A2 (en) |
| HU (1) | HUT76322A (en) |
| IL (1) | IL111338A0 (en) |
| JO (1) | JO1866B1 (en) |
| MA (1) | MA23356A1 (en) |
| MD (1) | MD960168A (en) |
| NO (1) | NO961547L (en) |
| OA (1) | OA10579A (en) |
| PE (1) | PE5596A1 (en) |
| PL (1) | PL314008A1 (en) |
| SK (1) | SK50696A3 (en) |
| UY (1) | UY23844A1 (en) |
| WO (1) | WO1995011028A1 (en) |
| ZA (1) | ZA948191B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07188052A (en) * | 1993-12-27 | 1995-07-25 | Sanwa Kagaku Kenkyusho Co Ltd | Interferon activity-enhancing agent and antivirus activity-enhancing composition containing the enhancing agent and interferon |
| US5756479A (en) * | 1994-12-29 | 1998-05-26 | Research Development Foundation | Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase |
| US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| US6933285B2 (en) * | 2002-05-10 | 2005-08-23 | The Ohio State University | Flavin N-oxides: new anti-cancer agents and pathogen eradication agents |
| ITTO20020622A1 (en) | 2002-07-16 | 2004-01-16 | Dayco Europe Srl | INTEGRATED PULLEY-TORSIONAL DAMPER GROUP |
| US20060293335A1 (en) * | 2002-08-02 | 2006-12-28 | Qishou Xu | Riboflavin derivative and its manufacture and uses |
| EP2545788A1 (en) * | 2011-07-13 | 2013-01-16 | Martin Hulliger | Dietary multi-component system |
| JP2018131410A (en) * | 2017-02-15 | 2018-08-23 | ヒノキ新薬株式会社 | Caspase-3 inhibitor and use thereof |
| US11497749B2 (en) * | 2017-10-24 | 2022-11-15 | Lunella Biotech, Inc. | Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration |
| CN114126603A (en) * | 2019-07-09 | 2022-03-01 | 帝斯曼知识产权资产管理有限公司 | Reduction of viral activity of elaverde with riboflavin or DHA |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4219545A (en) * | 1979-03-23 | 1980-08-26 | Collins Calvin E | Treatment of infectious keratoconjunctivitis in animals |
| US4264601A (en) * | 1979-06-12 | 1981-04-28 | The Board Of Regents Of The University Of Oklahoma | Antihypertensive agents and their use in treatment of hypertension |
| US4500524A (en) * | 1982-09-15 | 1985-02-19 | Trustees Of Boston University | Tranquilizing and reducing or preventing seizures |
| WO1991002529A2 (en) * | 1989-08-14 | 1991-03-07 | John Bennett Kizer | Product and method for killing abnormal vertebrate cells |
| JP2727471B2 (en) * | 1989-09-14 | 1998-03-11 | 三井農林株式会社 | Influenza virus infection prevention agent |
| US5192264A (en) * | 1989-10-06 | 1993-03-09 | The Beth Israel Hospital Association | Methods and apparatus for treating disease states using oxidized lipoproteins |
| US5217716A (en) * | 1990-07-18 | 1993-06-08 | The Beth Israel Hospital Association | Method for treating viral infections using oxidized lipoproteins |
| FR2674753B1 (en) * | 1991-04-02 | 1995-03-10 | Jean Berque | NEW THERAPEUTIC INDICATIONS, PARTICULARLY FOR THE TREATMENT OF AIDS, OF AN ALREADY EXISTING MEDICINAL PRODUCT FROM A DENIMOUS MOLECULE OF CONTRAINDICATIONS AND ADVERSE REACTIONS. |
| NZ244270A (en) * | 1991-09-13 | 1995-07-26 | Eisai Co Ltd | Injectable composition comprising riboflavin |
| WO1993010784A1 (en) * | 1991-11-25 | 1993-06-10 | University Of Michigan | Therapeutic composition and method for preventing reperfusion injury |
| JP3073309B2 (en) * | 1992-03-27 | 2000-08-07 | 雪印乳業株式会社 | Sialic acid-bound 5-deazaflavin compounds |
-
1993
- 1993-10-19 GB GB939321558A patent/GB9321558D0/en active Pending
-
1994
- 1994-01-19 JO JO19941866A patent/JO1866B1/en active
- 1994-05-18 CA CA2123825A patent/CA2123825A1/en active Pending
- 1994-10-18 MA MA23679A patent/MA23356A1/en unknown
- 1994-10-19 GB GB9421099A patent/GB2283913A/en not_active Withdrawn
- 1994-10-19 CO CO94047671A patent/CO4520283A1/en unknown
- 1994-10-19 PE PE1994253128A patent/PE5596A1/en not_active Application Discontinuation
- 1994-10-19 HR HR9321558.0A patent/HRP940688A2/en not_active Application Discontinuation
- 1994-10-19 AP APAP/P/1994/000695A patent/AP620A/en active
- 1994-10-19 WO PCT/GB1994/002292 patent/WO1995011028A1/en not_active Application Discontinuation
- 1994-10-19 HU HU9601006A patent/HUT76322A/en unknown
- 1994-10-19 EP EP94930272A patent/EP0739208A1/en not_active Withdrawn
- 1994-10-19 BR BR9407862A patent/BR9407862A/en not_active Application Discontinuation
- 1994-10-19 PL PL94314008A patent/PL314008A1/en unknown
- 1994-10-19 ZA ZA948191A patent/ZA948191B/en unknown
- 1994-10-19 IL IL11133894A patent/IL111338A0/en unknown
- 1994-10-19 JP JP7511518A patent/JPH09505804A/en active Pending
- 1994-10-19 UY UY23844A patent/UY23844A1/en unknown
- 1994-10-19 CZ CZ961137A patent/CZ113796A3/en unknown
- 1994-10-19 EE EE9600057A patent/EE9600057A/en unknown
- 1994-10-19 CN CN94194350A patent/CN1140992A/en active Pending
- 1994-10-19 CA CA002174552A patent/CA2174552A1/en not_active Abandoned
- 1994-10-19 SK SK506-96A patent/SK50696A3/en unknown
- 1994-10-19 AU AU79437/94A patent/AU7943794A/en not_active Abandoned
-
1996
- 1996-04-18 NO NO961547A patent/NO961547L/en unknown
- 1996-04-18 OA OA60815A patent/OA10579A/en unknown
- 1996-05-17 BG BG100599A patent/BG100599A/en unknown
- 1996-05-17 MD MD96-0168A patent/MD960168A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1140992A (en) | 1997-01-22 |
| MD960168A (en) | 1998-04-30 |
| HUT76322A (en) | 1997-08-28 |
| HU9601006D0 (en) | 1996-06-28 |
| NO961547D0 (en) | 1996-04-18 |
| EE9600057A (en) | 1996-10-15 |
| PE5596A1 (en) | 1996-04-18 |
| GB9421099D0 (en) | 1994-12-07 |
| IL111338A0 (en) | 1994-12-29 |
| EP0739208A1 (en) | 1996-10-30 |
| AP620A (en) | 1997-10-14 |
| SK50696A3 (en) | 1997-01-08 |
| CA2174552A1 (en) | 1995-04-27 |
| CO4520283A1 (en) | 1997-10-15 |
| BR9407862A (en) | 1997-05-20 |
| GB9321558D0 (en) | 1993-12-08 |
| ZA948191B (en) | 1995-06-08 |
| CZ113796A3 (en) | 1996-11-13 |
| BG100599A (en) | 1997-02-28 |
| JO1866B1 (en) | 1995-12-27 |
| HRP940688A2 (en) | 1997-04-30 |
| NO961547L (en) | 1996-06-19 |
| PL314008A1 (en) | 1996-08-05 |
| AU7943794A (en) | 1995-05-08 |
| JPH09505804A (en) | 1997-06-10 |
| GB2283913A (en) | 1995-05-24 |
| AP9400695A0 (en) | 1995-01-31 |
| CA2123825A1 (en) | 1995-04-20 |
| WO1995011028A1 (en) | 1995-04-27 |
| OA10579A (en) | 2002-06-19 |
| MA23356A1 (en) | 1995-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2147294T3 (en) | THERAPEUTIC COMPOUNDS. | |
| ES2087639T3 (en) | THERAPEUTIC NUCLEOSIDES. | |
| DE68922903D1 (en) | Antiviral pyrimidine and purine compounds, processes for their preparation and pharmaceutical preparations containing them. | |
| ES2069582T3 (en) | THERAPEUTIC NUCLEOSIDES. | |
| ECSP941104A (en) | DERIVATIVES OF 2,6 DIAMINOPURINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
| PT91108A (en) | A process for the preparation of a pharmaceutical composition comprising an active ingredient such as a colic acid salt and an inhibitor product for activating the absorption of the active ingredient by the human body | |
| BR0209658A (en) | 4-Amino-5-phenyl-7-1-cyclobutyl-pyrrolo [2,3-d] pyrimidine derivatives | |
| GR3007790T3 (en) | ||
| ES2133138T3 (en) | THERAPEUTIC NUCLEOSIDES. | |
| ES2188656T3 (en) | ANTIVIRAL COMPOSITION FOR THE CICATRIZATION OF A WOUND THAT CONTAINS A PIRUVATE, AN ANTIOXIDANT, A MIXED SATURATED FATTY ACIDS AND AN ANTI-VIRAL COMPOUND. | |
| ES2087916T3 (en) | DERIVATIVE OF BICYCLIC PIRIMIDINE, METHOD TO PRODUCE THE SAME, AND PHARMACEUTICAL PREPARATION THAT CONTAINS THE SAME AS AN ACTIVE INGREDIENT. | |
| UY23844A1 (en) | ANTIVIROSIC AGENTS. | |
| ES2084579T3 (en) | USE OF BUSPIRONE IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOL ABUSE. | |
| AR013001A1 (en) | DERIVATIVES OF PIPERAZINE, PROCEDURES TO PREPARE THEM, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, THEIR USE AS A MEDICINAL PRODUCT AND THE METHOD FOR TREATING DISEASES MEDIATED BY TACHININ. | |
| BR9401199A (en) | Drug preparations, process for the preparation of a medicine preparation, process for the preparation of a medicine formulation. | |
| PT95868A (en) | A PROCESS FOR THE PREPARATION OF A DELAYED LIBERATION COMPOSITION COMPOSING POLYPROPENOIC ACID AND AN ACTIVE MEDICINE FOR TREATMENT OF PERIODONTIC DISEASES | |
| AR019053A1 (en) | USE OF 2'2'-DIFLUORONUCLEOSIDS FOR THE PREPARATION OF A PHARMACEUTICAL MEDICINAL PRODUCT AND COMPOSITION AND PHARMACEUTICAL PRODUCT CONTAINING THEM | |
| AR016233A1 (en) | TIENOPIRIMIDINAS, A PROCEDURE FOR THEIR PREPARATION, THE USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, THE PHARMACEUTICAL COMPOSITIONS THAT THEY CONNECT, AND A PROCEDURE TO OBTAIN THESE PHARMACEUTICAL COMPOSITIONS. | |
| ES2032628T3 (en) | METHOD TO PRODUCE A SOLID PHARMACEUTICAL PREPARATION. | |
| ES2108014T3 (en) | ANTIVIRAL COMPOSITION OF 3'-AZIDO-2 ', 3'-DIDEOXI-5-METHYLCITIDINE. | |
| DK561089A (en) | USE OF LACTAMIMIDES FOR THE PREPARATION OF MEDICINAL PRODUCTS | |
| ES8400742A1 (en) | Tricyclic ethers, processes for their preparation and their use as medicaments. | |
| PT91153A (en) | PROCESS FOR THE PREPARATION OF AN ESTER OF 9- (2-HYDROXY-ETHOXY-METHYL) GUANIN AND COMPOSITIONS CONTAINING | |
| ES2052922T3 (en) | THERAPEUTIC NUCLEOSIDES. | |
| ES2129448T3 (en) | USE OF 2- (2-NITRO-4-TRIFLUOROMETILBENZOIL) -1,3-CYCLLOHEXANODIONA IN THE TREATMENT OF THYROSINEMIA AND PHARMACEUTICAL COMPOSITIONS. |